Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07825857 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder

Name: Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder — clinical trial record (NCT07825857)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: T-STEM

StatusNot Yet Recruiting

PhasePhase 2

SponsorUniversity of Texas Southwestern Medical Center

Started2026-10-01

View on ClinicalTrials.gov ↗

University of Texas Southwestern Medical Center

297 trials monitored

See 22 trials at risk

This is a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial evaluating the tolerability, safety, and preliminary efficacy of tirzepatide for the treatment of individuals with moderate or severe methamphetamine use disorder (MtUD). The central hypothesis of the proposed research is that tirzepatide is a safe and potentially efficacious treatment of MtUD. Participants will undergo study procedures over 32 weeks, including: 1. completing self-assessments 2. undergo brief physical and review of medical and psychiatric history 3. provide urine and blood samples 4. medical management sessions 5. weekly subcutaneous study medication injections

Trial Details

NCT Number	NCT07825857
Lead Sponsor	University of Texas Southwestern Medical Center Collaborators: National Institute on Drug Abuse (NIDA)
Conditions	Methamphetamine Use Disorder
Enrollment	228 participants
Start Date	2026-10-01
Primary Completion	2031-07-01 (estimated)
Study Completion	2031-08 (estimated)
Updated on ClinicalTrials.gov	2026-09-23